Ad is loading...
PEMGX
Price
$45.16
Change
-$0.64 (-1.40%)
Updated
Nov 15 closing price
PMBCX
Price
$37.47
Change
-$0.53 (-1.39%)
Updated
Nov 15 closing price
Ad is loading...

PEMGX vs PMBCX

Header iconPEMGX vs PMBCX Comparison
Open Charts PEMGX vs PMBCXBanner chart's image
Principal MidCap A
Price$45.16
Change-$0.64 (-1.40%)
VolumeN/A
CapitalizationN/A
Principal MidCap C
Price$37.47
Change-$0.53 (-1.39%)
VolumeN/A
CapitalizationN/A
PEMGX vs PMBCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
PEMGX vs. PMBCX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PEMGX is a Buy and PMBCX is a Buy.

FUNDAMENTALS
Fundamentals
PEMGX (29.3B) and PMBCX (29.3B) have equal amount of cash in the bank . PEMGX (0.00) and PMBCX (0.00) have matching dividends . PEMGX was incepted earlier than PMBCX: PEMGX (19 years) vs PMBCX (18 years). PEMGX (10.10) and PMBCX (10.10) have comparable annual turnover. PEMGX (1000) and PMBCX (1000) have matching initial minimum investment requirements. PEMGX annual gain was more profitable for investors over the last year : 28.88 vs. PMBCX (27.23). PEMGX return over 5 years is better than : 47.78 vs. PMBCX (37.86).
PEMGXPMBCXPEMGX / PMBCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence19 years18 years-
Gain YTD22.98522.132104%
Front LoadN/AN/A-
Min. Initial Investment10001000100%
Min. Initial Investment IRAN/AN/A-
Net Assets29.3B29.3B100%
Annual Yield % from dividends0.000.00-
Returns for 1 year28.8827.23106%
Returns for 3 years2.40-2.37-101%
Returns for 5 years47.7837.86126%
Returns for 10 years102.9878.00132%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WEX179.08-1.83
-1.01%
WEX
EHAB7.35-0.09
-1.21%
Enhabit
BW1.77-0.07
-3.80%
Babcock & Wilcox Enterprises
TTNP3.81-0.19
-4.64%
Titan Pharmaceuticals
ARWR18.57-2.84
-13.26%
Arrowhead Pharmaceuticals